Form 8-K

8-K — MANNKIND CORP

Accession: 0001193125-26-335016

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0000899460

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — mnkd-20260805.htm (Primary)

EX-99.1 (mnkd-ex99_1.htm)

GRAPHIC (img208524907_0.gif)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: mnkd-20260805.htm · Sequence: 1

8-K

0000899460false00008994602026-08-052026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 05, 2026

MannKind Corporation

(Exact name of Registrant as Specified in Its Charter)

Delaware

000-50865

13-3607736

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

1 Casper Street

Danbury, Connecticut

06810

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (818) 661-5000

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

MNKD

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2026, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1

Press release dated August 5, 2026

Exhibit 104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MannKind Corporation

Date: August 5, 2026

By:

/s/ David Thomson, Ph.D., J.D.

David Thomson, Ph.D., J.D.

Corporate Vice President, General Counsel and Secretary

EX-99.1

Filename: mnkd-ex99_1.htm · Sequence: 2

EX-99.1

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

•

Achieved three major catalysts to drive future growth:

Launched the pediatric indication of Afrezza® following FDA approval

FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD

Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement

•

Encouraging early momentum in Afrezza pediatric launch

1 in 3 of the top 100 pediatric insulin writers have prescribed

•

Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025

•

Conference call and webcast today at 4:30 p.m. ET

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD)

a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the second quarter of 2026, and provided a business update.

“This was a transformative period for MannKind, during which we delivered all three major catalysts we set out to achieve in 2026,” said Michael Castagna, Chief Executive Officer of MannKind. “The two recent FDA approvals are expected to fuel our near-term growth opportunities to help patients living with diabetes, heart failure and CKD. The positive Phase 1b INFLO-1 results for MNKD-201 reduces development risk and strengthens our confidence in the ability of our platform to help people living with IPF and other fibrotic diseases. Together, these milestones validate our diversification strategy and position MannKind for sustainable growth.”

Business Update and Upcoming Milestones

Commercial Products

•

Revenue from marketed products (Afrezza, Furoscix®) grew 27% from Q1 2026 to Q2 2026

Furoscix

•

Furoscix (furosemide injection) generated $22.2 million in net sales for Q2 2026

•

Continued growth in Integrated Delivery Networks, increasing doses purchased by 36% over Q1 2026

•

Record number of nephrology units dispensed, increasing by 67% over Q1 2026

•

Received FDA approval of Furoscix ReadyFlow™ on July 23, 2026, the first and only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema in adults with heart failure (HF) or chronic kidney disease (CKD); expected to be commercially available in late August

Afrezza

•

Afrezza (insulin human) Inhalation Powder generated $17.0 million in net sales for Q2 2026

•

Received FDA approval of Afrezza on May 29, 2026 for use in children and adolescents ages 6 and older living with diabetes

•

Awarded Breakthrough T1D grant supporting advancement of INHALE-1ST, a pediatric trial of Afrezza in youth with newly diagnosed type 1 diabetes

Development

Nintedanib DPI (MNKD-201)

•

Topline data readout of U.S. Phase 1b INFLO-1 demonstrates safety and tolerability in IPF patients

•

Site activation and enrollment underway in the global Phase 2 INFLO-2 study

Ralinepag DPI (MNKD-1501)

•

On track for IND filing by year end

•

Received a $5 million payment from United Therapeutics (UT) to support the rapid advancement of ralinepag DPI

Corporate Update

•

Cash, cash equivalents and investments as of June 30, 2026, totaled $111 million

•

Closed $50 million private placement on July 24, 2026; proceeds will fund the $45 million CVR payment triggered by the FDA approval of Furoscix ReadyFlow

Second Quarter 2026 Financial Results

Revenues

Three Months

Ended June 30,

2026

2025

$ Change

% Change

Revenues

(Dollars in thousands)

Afrezza

17,021

18,329

(1,308

)

Furoscix

22,191

—

22,191

N/A

V-Go®

2,770

4,125

(1,355

)

(33

Collaborations and services

35,022

22,845

12,177

Royalties

32,370

31,228

1,142

Total revenues

109,374

76,527

32,847

Total revenues for the second quarter of 2026 increased compared to the same period in the prior year due to the addition of Furoscix to our product portfolio through the October 7, 2025 acquisition of scPharma, as well as increases in collaborations and services revenue, and royalties. The increase in collaborations and services revenue was primarily attributable to increased product sold to UT and revenue earned related to the development of ralinepag DPI. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.

Operating Expenses and Other Financial Highlights



Cost of goods sold – commercial, excluding amortization of acquired intangible assets, was $14.4 million for the three months ended June 30, 2026, compared to $4.6 million for the same period in 2025.



The increase is primarily attributable to the inclusion of Furoscix into our product portfolio following the acquisition of scPharma in October 2025. Gross margin percentage decreased in the current period due to the inclusion of Furoscix, which has a lower gross margin percentage than Afrezza.



Research and development expenses were $18.0 million for the three months ended June 30, 2026, compared to $13.7 million for the same period in 2025, an increase of 32%.



The increase was primarily attributable to the development of the Furoscix ReadyFlow Formulation as well as higher personnel costs following the acquisition of scPharma and increased development costs for MNKD-201, which has begun enrolling subjects. The increase was partially offset by lower clinical development expenses resulting from the discontinuation of the ICoN-1 clinical study for MNKD-101 and the completion of the Afrezza pediatric study (INHALE-1).



Selling, general and administrative expenses were $58.3 million for the three months ended June 30, 2026, compared to $31.6 million for the same period in 2025, an increase of 84%.



The increase was primarily related to costs associated with the promotion and support of Furoscix, as well as expanding our field-based teams and activities to support the launches associated with the recent approvals of the pediatric indication for Afrezza and the Furoscix ReadyFlow Autoinjector.

Six Months Ended June 30, 2026

Revenues

Six Months

Ended June 30,

2026

2025

$ Change

% Change

Revenues

(Dollars in thousands)

Afrezza

32,294

33,216

(922

)

Furoscix

37,684

—

37,684

N/A

V-Go

5,911

8,211

(2,300

)

(28

Collaborations and services

58,536

52,221

6,315

Royalties

65,119

61,233

3,886

Total revenues

199,544

154,881

44,663

Total revenues for the six months ended June 30, 2026 increased compared to the same period in the prior year due to the addition of Furoscix to our product portfolio through the October 7, 2025 acquisition of scPharma, as well as increases in collaborations and services revenue, and royalties. The increase in collaborations and services revenue was primarily attributable to an increase in revenue earned related to the development of ralinepag DPI. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.

Operating Expenses and Other Financial Highlights



Cost of goods sold – commercial, excluding amortization of acquired intangible assets, was $21.9 million for the six months ended

June 30, 2026, compared to $8.4 million for the same period in 2025.





Research and development expenses were $35.2 million for the six months ended June 30, 2026, compared to $24.7 million for the same period in 2025, an increase of 43%.





Selling, general and administrative expenses were $112.4 million for the six months ended June 30, 2026, compared to $56.6 million for the same period in 2025, an increase of 98%.



Conference Call and Webcast

MannKind will host a conference call and webcast to discuss these results today at 4:30 p.m. Eastern Time. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours after the call and accessible for approximately 90 days.

About MannKind

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding the timing for expected commercial availability of Furoscix ReadyFlow and the broadened growth potential for Furoscix; the timing of a planned IND filing of ralinepag DPI; expectations regarding MannKind’s ongoing and planned clinical trials and nonclinical studies; and our being positioned for sustainable growth. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” “goal,” “potential,” “prepare,” “opportunity” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with developing product candidates; risks and uncertainties related to unforeseen delays that may impact the timing of clinical trials and reporting data; risks associated with safety and other complications of our products and product candidates; risks associated with the regulatory review process; risks associated with competition; manufacturing risks; market adoption risks; and other risks detailed in MannKind’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Tyvaso DPI is a trademark of United Therapeutics Corporation.

AFREZZA, FUROSCIX, FUROSCIX READYFLOW, MANNKIND, and V-GO are trademarks of MannKind Corporation.

MannKind Contacts:

Investor Relations

Kate Miranda

Email: ir@mnkd.com

Media Relations

Christie Iacangelo

Email: media@mnkd.com

MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months

Ended June 30,

Six Months

Ended June 30,

2026

2025

2026

2025

(In thousands except per share data)

Revenues:

Commercial product sales

41,982

22,454

75,889

41,427

Collaborations and services

35,022

22,845

58,536

52,221

Royalties

32,370

31,228

65,119

61,233

Total revenues

109,374

76,527

199,544

154,881

Expenses:

Cost of goods sold – commercial, excluding amortization of acquired intangible assets

14,409

4,607

21,917

8,375

Cost of revenue – collaborations and services

15,131

15,961

25,094

29,709

Research and development

18,001

13,675

35,232

24,697

Selling, general and administrative

58,302

31,622

112,389

56,636

Amortization of acquired intangible assets

4,367

—

8,734

—

(Gain) loss on foreign currency transaction

(486

)

5,363

(1,804

)

7,872

Total expenses

109,724

71,228

201,562

127,289

(Loss) income from operations

(350

)

5,299

(2,018

)

27,592

Other income (expense):

Interest income, net

1,022

1,832

2,452

3,788

Interest expense

(11,894

)

(285

)

(19,372

)

(4,930

)

Interest expense on liability for sale of future royalties

(510

)

(3,473

)

(3,073

)

(7,050

)

Interest expense on financing liability

(2,414

)

(2,433

)

(4,807

)

(4,843

)

Loss on settlement of debt

—

(917

)

—

Other expense

(4,992

)

—

(7,769

)

—

Total other expense

(18,788

)

(4,359

)

(33,486

)

(13,035

)

(Loss) income before income tax (benefit) expense

(19,138

)

940

(35,504

)

14,557

Income tax (benefit) expense

(106

)

272

147

731

Net (loss) income

(19,032

)

668

(35,651

)

13,826

Net (loss) income per share – basic

(0.06

)

0.00

(0.12

)

0.05

Weighted average shares used to compute net (loss) income

per share – basic

309,191

304,954

308,732

304,222

Net (loss) income per share – diluted

(0.06

)

0.00

(0.12

)

0.04

Weighted average shares used to compute net (loss) income

per share – diluted

309,191

311,484

308,732

312,381

MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

June 30, 2026

December 31, 2025

(In thousands except share

and per share data)

ASSETS

Current assets:

Cash and cash equivalents

52,929

74,882

Short-term investments

58,201

96,464

Accounts receivable, net

43,207

38,367

Inventory

44,419

35,313

Prepaid expenses and other current assets

46,956

46,553

Total current assets

245,712

291,579

Restricted cash

749

745

Long-term investments

—

5,012

Property and equipment, net

85,160

82,423

Goodwill

67,595

Developed technology - on-body infusor

181,389

190,027

IPR&D - ReadyFlow Formulation

129,600

Other intangible assets

4,976

5,072

Other assets

17,123

20,129

Total assets

732,304

792,182

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities:

Accounts payable

11,042

9,034

Accrued expenses and other current liabilities

60,768

64,628

Senior convertible notes – current

—

36,280

Liability for sale of future royalties – current

14,292

14,298

Contingent consideration – current

34,015

21,132

Financing liability – current

10,486

10,328

Deferred revenue – current

11,085

15,331

Recognized loss on purchase commitments – current

1,210

—

Total current liabilities

142,898

171,031

Liability for sale of future royalties – long term

133,552

136,985

Financing liability – long term

92,497

93,092

Deferred revenue – long term

36,857

39,977

Recognized loss on purchase commitments – long term

62,922

65,952

Operating lease liability

9,687

10,689

Contingent consideration – long term

—

5,114

Milestone liabilities

2,003

Term loan

319,085

318,361

Total liabilities

799,501

843,204

Commitments and contingencies

Stockholders' deficit:

Undesignated preferred stock, $0.01 par value – 10,000,000 shares authorized;

no shares issued or outstanding as of June 30, 2026 or December 31, 2025

—

Common stock, $0.01 par value – 800,000,000 shares authorized;

309,911,682 and 307,832,587 shares issued and outstanding as of

June 30, 2026 and December 31, 2025, respectively

3,099

3,078

Additional paid-in capital

3,161,330

3,141,741

Accumulated other comprehensive (loss) income

(19

)

115

Accumulated deficit

(3,231,607

)

(3,195,956

)

Total stockholders' deficit

(67,197

)

(51,022

)

Total liabilities and stockholders' deficit

732,304

792,182

Non-GAAP Measures

To supplement our condensed consolidated financial statements presented under GAAP, we are presenting non-GAAP net (loss) income and non-GAAP net (loss) income per share – basic, which are non-GAAP financial measures. We are providing these non-GAAP financial measures to disclose additional information to facilitate the comparison of past and present operations, and they are among the indicators management uses as a basis for evaluating our financial performance. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results, provide management and investors with an additional understanding of our business operating results, including underlying trends.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our non-GAAP financial measures; and we may in the future

cease to exclude items that we have historically excluded for purposes of our non-GAAP financial measures. Likewise, we may determine to modify the nature of adjustments to arrive at our non-GAAP financial measures. Because of the non-standardized definitions of non- GAAP financial measures, the non-GAAP financial measures as used by us in this report have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

The following table reconciles our financial measures for net (loss) income and net (loss) income per share ("EPS") for basic weighted average shares as reported in our condensed consolidated statement of operations to a non-GAAP presentation:

Three Months

Ended June 30,

Six Months

Ended June 30,

2026

2025

2026

2025

Net Loss

Basic EPS

Net Income

Basic EPS

Net Loss

Basic EPS

Net Income

Basic EPS

GAAP reported net (loss) income

(19,032

)

(0.06

)

668

0.00

(35,651

)

(0.12

)

13,826

0.05

Non-GAAP adjustments:

Stock compensation

10,226

0.03

7,520

0.03

16,681

0.05

12,905

0.04

Interest expense on liability for sale of future royalties

510

0.00

3,473

0.01

3,073

0.01

7,050

0.02

Sold portion of royalty revenue (1)

(3,237

)

(0.01

)

(3,123

)

(0.01

)

(6,512

)

(0.02

)

(6,123

)

(0.02

)

(Gain) loss on foreign currency transaction

(486

)

0.00

5,363

0.02

(1,804

)

(0.01

)

7,872

0.03

Amortization of intangible assets acquired

4,367

0.01

—

8,734

0.03

—

Change in fair value of contingent consideration

4,992

0.02

—

7,769

0.03

—

Loss on settlement of debt

—

917

0.00

—

Non-GAAP adjusted net (loss) income

(2,660

)

(0.01

)

13,901

0.05

(6,793

)

(0.03

)

35,530

0.12

Weighted average shares used to compute net (loss) income per share – basic

309,191

304,954

308,732

304,222

(1)

Represents the non-cash portion of the 1% royalty on net sales of Tyvaso DPI earned during the three and six months ended June 30, 2026 and 2025 which is remitted to the royalty purchaser and recognized as royalties from collaborations in our condensed consolidated statements of operations.

GRAPHIC

Filename: img208524907_0.gif · Sequence: 3

Binary file (1911 bytes)

Download img208524907_0.gif

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Document And Entity Information

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 05, 2026

Entity Registrant Name

MannKind Corporation

Entity Central Index Key

0000899460

Entity Emerging Growth Company

false

Entity File Number

000-50865

Entity Incorporation, State or Country Code

Entity Tax Identification Number

13-3607736

Entity Address, Address Line One

1 Casper Street

Entity Address, City or Town

Danbury

Entity Address, State or Province

Entity Address, Postal Zip Code

06810

City Area Code

(818)

Local Phone Number

661-5000

Entity Information, Former Legal or Registered Name

N/A

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

MNKD

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration